NGVTBasic Materials · Specialty ChemicalsThe 3 Wall Street analysts covering Ingevity Corp. hold a median 12-month price target of $90 — +29.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 97 of 100 as at 24 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Ingevity Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (99): The share count has been shrinking and the company is not leaning on new borrowing.
Growth (39): Sales and profits are flat, shrinking, or growing more slowly than they were.
Size (32): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on NGVT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +29.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 Feb 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 27 Feb 2026 | Wells Fargo | Maintains | Equal-Weight | $65 → $75 |
| 29 Jan 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 19 Dec 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 10 Dec 2025 | BMO Capital | Maintains | Outperform | — |
| 12 Nov 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 5 Sept 2025 | BMO Capital | Maintains | Outperform | — |
| 7 Aug 2025 | BMO Capital | Maintains | Outperform | — |
| 14 July 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 7 May 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 9 Apr 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 26 Feb 2025 | BMO Capital | Upgrade | Outperform | — |
| 20 Feb 2025 | BMO Capital | Maintains | Market Perform | — |
| 31 Oct 2024 | BMO Capital | Maintains | Market Perform | — |
| 30 Sept 2024 | BMO Capital | Maintains | Market Perform | — |
| 5 Aug 2024 | BMO Capital | Maintains | Market Perform | — |
| 5 Aug 2024 | Wells Fargo | Maintains | Equal-Weight | — |
| 1 Aug 2024 | Oppenheimer | Maintains | Outperform | — |
| 11 July 2024 | Wells Fargo | Maintains | Equal-Weight | — |
| 8 May 2024 | BMO Capital | Maintains | Market Perform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
NGVT appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 23 Oct 2026, Ingevity Corp. returned +23.5% against +14.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 7% of US stocks
Cheaper than 51% of US stocks
Cheaper than 2% of US stocks
Cheaper than 39% of US stocks
Higher than 20% of US stocks
Higher than 24% of US stocks
Higher than 55% of US stocks
Higher than 87% of US stocks
Higher than 59% of US stocks
Higher than 87% of US stocks
Higher than 93% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Ingevity Corp. has a market value of $2.4B and an enterprise value of $3.5B.
Revenue in the twelve months to 30 June 2026: $1.2B. The latest quarter shrank 5.2% year on year.
Net income over the same four quarters: $54.0M, a 4.7% net margin.
Diluted earnings per share, trailing twelve months: $1.47.
Free cash flow in the twelve months to 30 June 2026: $154.9M, after $56.1M of capital spending.
Ingevity Corp. spent $143.1M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 99.5×; forward P/E: 11.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Ingevity Corp. employs 1,400 people — $829K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Ingevity Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Ingevity reported second-quarter adjusted EBITDA of $115 million, supported by favorable pricing, product mix and volumes. The company also raised its 2026 earnings guidance.
Why it matters — The results and higher guidance are relevant to NGVT watchers assessing the company’s earnings performance and outlook.
The article says Ingevity’s portfolio reshaping, acquisitions and strong cash flow support growth, while weakness in APT and macroeconomic risks cloud the outlook.
Why it matters — NGVT watchers may weigh the stated growth supports against APT weakness and broader macro risks when assessing the company’s outlook.
Ingevity announced that it will release its third-quarter 2026 earnings after the stock market closes on Wednesday, November 4, 2026.
Why it matters — NGVT watchers can note the scheduled timing of the company’s third-quarter earnings release.
Ingevity Corp. (NGVT) shares have rallied 31% over the past year. The gains are attributed to portfolio optimization, capacity investments, and debt reduction, which have bolstered confidence in the company's long-term growth prospects.
Why it matters — A NGVT watcher would note that the company's strategic actions are strengthening investor confidence in its long-term growth trajectory.
Ingevity is nearing completion of a strategic portfolio transformation that narrows its focus to its Performance Materials and Pavement Technologies businesses, according to President and CEO David Li during a Water Tower Research conference session. The company is also eyeing growth opportunities in filtration and warm-mix technologies.
Why it matters — NGVT watchers would track this portfolio transformation since it signals how the company intends to focus its resources and pursue emerging growth areas like filtration and warm-mix applications.
The 3 Wall Street analysts covering Ingevity Corp. have a median 12-month price target of $90, with estimates ranging from $85 to $92. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Ingevity Corp., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ingevity Corp. 97 out of 100 across roughly 4,600 US stocks as at 24 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 24 Oct 2026, Ingevity Corp. ranks 97 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (99 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +29.2% from the last close, and Ticker Nerd's factor model ranks Ingevity Corp. 97 out of 100 as at 24 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Ingevity Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NGVT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $85 to $92 over the next 12 months.
Ingevity Corp. returned +23.5% over the 12 months to 23 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Ingevity Corporation is a specialty materials and chemical manufacturing company that develops and sells activated carbon products, specialty chemicals, and engineered polymers. Its products are used in emissions control, industrial purification, pavement technologies, adhesives, coatings, resins, elastomers, lubricants, agrochemicals, and other performance applications.
The most recent item we track (Zacks Investment Research, 15 Oct 2026): "Is NGVT Positioned for Further Adjusted EBITDA Improvement?". Ingevity reported second-quarter adjusted EBITDA of $115 million, supported by favorable pricing, product mix and volumes. The company also raised its 2026 earnings guidance.
Ingevity Corporation is a specialty materials and chemical manufacturing company that develops and sells activated carbon products, specialty chemicals, and engineered polymers. Its products are used in emissions control, industrial purification, pavement technologies, adhesives, coatings, resins, elastomers, lubricants, agrochemicals, and other performance applications. The company serves customers across a broad range of industries, including automotive, infrastructure, water and process treatment, and industrial manufacturing. Ingevity organizes its business around Performance Materials, Performance Chemicals, and Advanced Polymer Technologies, with solutions designed to help customers improve product performance, durability, and process efficiency. Headquartered in North Charleston, South Carolina, Ingevity operates with a global commercial and manufacturing footprint spanning North America, Europe, Asia Pacific, and other international markets.
CEO Mr. David H. Li · 1,400 employees · United States · https://www.ingevity.com
